This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Link between effectiveness and cost data
The costs were obtained from the literature.
Study sample
Details of the study methods were presented elsewhere (Mehta et al., see Other Publications of Related Interest) . It is therefore impossible to say whether the sample size was determined in the planning stages of the study. Details of how the sample was selected were not provided in this paper. It was not reported whether any patients refused to participate or the number of exclusions.
Study design
Details of the study design were presented elsewhere (Mehta et al., 
see Other Publications of Related Interest).

Analysis of effectiveness
The effectiveness data recorded in this study were the prevalence of gonorrhoea and chlamydia in men and women.
Effectiveness results
The prevalence of gonorrhoea and chlamydia was 0.135 (range: 0.094 -0.175) in women and 0.138 (range: 0.084 -0.193) in men.
Clinical conclusions
The prevalence of gonorrhoea and chlamydia were similar in both men and women.
Modelling
A decision tree model was used to estimate the costs and the benefits. The time horizon of the model was 10 years.
Outcomes assessed in the review
The outcomes assessed were the probabilities of: The review also assessed the costs of treatment and complications.
Study designs and other criteria for inclusion in the review
Not stated.
Sources searched to identify primary studies
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Twelve studies were included in the review.
Methods of combining primary studies
The methods used to combine the data were not reported, but averages and maximum and minimum values appear to have been used.
Investigation of differences between primary studies
The authors do not appear to have investigated any differences between the primary studies, nor did they provide an explanation for any such differences.
Results of the review
The probabilities were as follows: Univariate and multivariate sensitivity analyses were carried out to investigate variability in the parameter data used.
Estimated benefits used in the economic analysis
Among women, the number of cases of gonorrhoea or chlamydia not treated was 1,073 with strategy 1, 713 with strategy 2, 706 with strategy 3, 574 with strategy 4, and 68 with strategy 5. The corresponding numbers of cases among men were 1,020 (strategy 1), 1,040 (strategy 2), 890 (strategy 3), 810 (strategy 4), and 70 (strategy 5), respectively.
Cost results
The costs obtained from the literature review were for: For women, the cost associated with treating the male partners of infected females was $12.93 (range: 2 -54.94). The cost associated with neonatal outcomes was $8.92 (range: 2.62 -48.03). The cost associated with untreated infections in women was $870.69 (range: 308.86 -2,107.07). Thus, the total cost was $892.54 (range: 313.48 -2,210.04).
For men, the cost associated with treating the female partners of infected males was $487.59 (range: 197.78 -1,313.70). The cost associated with neonatal outcomes was $4.99 (range: 1.47 -31.22). The cost associated with untreated infections in men was $25.87 (range: 15.50 -73.26). Thus, the total cost was $518.45 (range: 214.75 -1,418.18).
For women, the total costs were $961,000 for strategy 1, $1,042,245 for strategy 2, $966,245 for strategy 3, $913,245 for strategy 4, and $522,245 for strategy 5.
For men, the total costs were $532,000 for strategy 1, $923,245 for strategy 2, $752,245 for strategy 3, $798,245 for
NHS Economic Evaluation Database (NHS EED) Produced by the Centre for Reviews and Dissemination Copyright © 2019 University of York
Page: 5 / 7 strategy 4, and $498,245 for strategy 5.
Synthesis of costs and benefits
For women, comparing strategy 2 with strategy 1 (the standard) gave an incremental cost-effectiveness ratio (ICER) of $255.68. The ICER was $14.29 for strategy 3 versus the standard, -$95.70 for strategy 4 versus the standard, and -$436.57 for strategy 5 versus the standard.
For men, the ICER was $1,694.19 for strategy 3 versus the standard, $1,267.83 for strategy 4 versus the standard, and -$35.53 for strategy 5 versus the standard.
The sensitivity analysis indicated that the results were susceptible to variations in several parameters, such as the cost of LCR.
Authors' conclusions
The cost-effectiveness of screening was maximised in strategy 4 for women, when screening was carried out along with standard emergency department practice (EDP). Screening all women aged 18 to 31 years was more cost-effective than selective screening. This continued to be the case even when the prevalence of gonorrhoea and chlamydia ranged from 7 to 17.5%. Mass treatment cost less than standard practice for both men and women.
CRD COMMENTARY -Selection of comparators
The comparator was justified on the grounds that it represented standard practice. You should decide if this is a widely used heath technology in you own setting.
Validity of estimate of measure of effectiveness
The details of the analysis of the prevalence of gonorrhoea and chlamydia were not reported in this study. The study sample was representative of the study population. The authors did not state whether a systematic review of the literature was undertaken. They used data from the available studies selectively and did not consider the impact of differences between the primary studies when estimating the effectiveness.
Validity of estimate of measure of benefit
The estimation of benefits was modelled. The instrument (decision tree) used to derive the measure of health benefit was appropriate. The measure of health benefit used was the untreated cases of gonorrhoea or chlamydia. However, for meaningful comparisons in other disease areas, the use of quality-adjusted life-years would have been preferable.
Validity of estimate of costs
All the categories of cost relevant to the perspective adopted were included in the analysis. The costs and the quantities were not reported separately. A sensitivity analysis of the quantities was not conducted, whereas a sensitivity analysis of the prices was. The ranges used, which were derived from the literature, appear to have been appropriate.
infections were not included. These costs would have made the enhanced screening option even more cost-effective than estimated. The indirect costs of lost productivity and loss of leisure time were also not included, resulting in the underestimation of the total benefit of screening. Spontaneous cure and decreased compliance with multiple dose regimens were not modelled, and these would have decreased the cost-effectiveness of screening. Finally, it was assumed that inpatient antibiotic or surgical therapy would be 100% curative, even though inpatients are more likely to have serious infections.
